Cargando…

Effect of Adjuvant Radiation Dose on Survival in Patients with Esophageal Squamous Cell Carcinoma

SIMPLE SUMMARY: For patients with esophageal cancer, postoperative radiotherapy (PORT) improved LRFS. However, concerns about treatment-related toxicity issues limited its application. The authors found that for patients receiving upfront surgical resection, with adjuvant radiation dose (aRTD) escal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Weiming, Chang, Xiao, Zhang, Wencheng, Yang, Jingsong, Yu, Shufei, Deng, Wei, Ni, Wenjie, Zhou, Zongmei, Chen, Dongfu, Feng, Qinfu, Liang, Jun, Hui, Zhouguang, Wang, Lvhua, Gao, Shugeng, Lin, Yu, Chen, Xiaohui, Chen, Junqiang, Xiao, Zefen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9736548/ https://www.ncbi.nlm.nih.gov/pubmed/36497360 http://dx.doi.org/10.3390/cancers14235879

Ejemplares similares

Adjuvant radiotherapy for stage pN1M0 esophageal squamous cell carcinoma: Results from a Chinese two‐center study
por: Ni, Wenjie, et al.
Publicado: (2019)

Efficacy of intensity-modulated radiotherapy for resected thoracic esophageal squamous cell carcinoma
por: Zhang, Wencheng, et al.
Publicado: (2015)

Nomogram and recursive partitioning analysis to predict overall survival in patients with stage IIB-III thoracic esophageal squamous cell carcinoma after esophagectomy
por: Yu, Shufei, et al.
Publicado: (2016)

Recurrence risk stratification based on a competing-risks nomogram to identify patients with esophageal cancer who may benefit from postoperative radiotherapy
por: Chang, Xiao, et al.
Publicado: (2021)

A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma
por: Ni, Wenjie, et al.
Publicado: (2020)

Residual lymph node status is an independent prognostic factor in esophageal squamous cell Carcinoma with pathologic T0 after preoperative radiotherapy
por: Wang, Qifeng, et al.
Publicado: (2015)

Severe radiation-induced lymphopenia during postoperative radiotherapy or chemoradiotherapy has poor prognosis in patients with stage IIB-III after radical esophagectomy: A post hoc analysis of a randomized controlled trial
por: Ni, Wenjie, et al.
Publicado: (2022)

Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis
por: Han, Weiming, et al.
Publicado: (2022)

Salvage chemoradiation therapy for recurrence after radical surgery or palliative surgery in esophageal cancer patients: a prospective, multicenter clinical trial protocol
por: Chang, Xiao, et al.
Publicado: (2020)

Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy
por: Wang, Wenhui, et al.
Publicado: (2019)

Definitive Simultaneous Integrated Boost Versus Conventional-Fractionated Intensity Modulated Radiotherapy for Patients With Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis
por: Li, Chen, et al.
Publicado: (2021)

Further understanding of an uncommon disease of combined small cell lung cancer: clinical features and prognostic factors of 114 cases
por: Men, Yu, et al.
Publicado: (2016)

The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC)
por: Men, Yu, et al.
Publicado: (2017)

Survival benefit of surgery in patients with clinical T4 esophageal cancer who achieved complete or partial response after neoadjuvant chemoradiotherapy or radiotherapy
por: Gao, Lin-Rui, et al.
Publicado: (2022)

Patterns of recurrence after surgery and efficacy of salvage therapy after recurrence in patients with thoracic esophageal squamous cell carcinoma
por: Ni, Wenjie, et al.
Publicado: (2020)

Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial
por: Hui, Zhouguang, et al.
Publicado: (2021)

Induction of PD-L1 expression by epidermal growth factor receptor–mediated signaling in esophageal squamous cell carcinoma
por: Zhang, Wencheng, et al.
Publicado: (2017)

Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score‐matched analysis
por: Li, Chen, et al.
Publicado: (2021)

A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer
por: Li, Chen, et al.
Publicado: (2019)

Applying post-neoadjuvant pathologic stage as prognostic tool in esophageal squamous cell carcinoma
por: Han, Weiming, et al.
Publicado: (2022)

Selection of proper candidates with resected pathological stage IIIA-N2 non-small cell lung cancer for postoperative radiotherapy
por: Hui, Zhouguang, et al.
Publicado: (2015)

Increased CYFRA 21-1, CEA and NSE are Prognostic of Poor Outcome for Locally Advanced Squamous Cell Carcinoma in Lung: A Nomogram and Recursive Partitioning Risk Stratification Analysis()()()
por: Wang, Jingbo, et al.
Publicado: (2018)

S-1–Based Chemoradiotherapy Followed by Consolidation Chemotherapy With S-1 in Elderly Patients With Esophageal Squamous Cell Carcinoma: A Multicenter Phase II Trial
por: Wang, Xin, et al.
Publicado: (2020)

A prognostic nomogram for overall survival after neoadjuvant radiotherapy or chemoradiotherapy in thoracic esophageal squamous cell carcinoma: a retrospective analysis
por: Deng, Wei, et al.
Publicado: (2017)

Expression of epidermal growth factor receptor is an independent prognostic factor for esophageal squamous cell carcinoma
por: Wang, Qifeng, et al.
Publicado: (2013)

Impact of thoracic radiation therapy after chemotherapy on survival in extensive‐stage small cell lung cancer: A propensity score‐matched analysis
por: Deng, Lei, et al.
Publicado: (2019)

Radiation Dose-Effect Relation in Patients with Esophageal Squamous Cell Carcinoma: A National Cancer Center Data and Literature-Based Analysis
por: Han, Weiming, et al.
Publicado: (2022)

The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy
por: Zhang, Tao, et al.
Publicado: (2020)

Postoperative radiotherapy for completely resected Masaoka stage III thymoma: a retrospective study of 65 cases from a single institution
por: Fan, Chengcheng, et al.
Publicado: (2013)

Tumor Compactness based on CT to predict prognosis after multimodal treatment for esophageal squamous cell carcinoma
por: Wang, Qifeng, et al.
Publicado: (2019)

Clinical outcomes and radiation pneumonitis after concurrent EGFR‐tyrosine kinase inhibitors and radiotherapy for unresectable stage III non‐small cell lung cancer
por: Xu, Kunpeng, et al.
Publicado: (2021)

Programmed death‐ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor
por: Zhang, Wencheng, et al.
Publicado: (2017)

Effectiveness of S-1–Based Chemoradiotherapy in Patients 70 Years and Older With Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial
por: Wang, Xin, et al.
Publicado: (2023)

Intensity modulated radiotherapy might be effective for locally advanced esophageal carcinosarcoma: A single center’s experience and review of literature
por: Yang, Siran, et al.
Publicado: (2022)

The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases
por: Wang, Chunyu, et al.
Publicado: (2019)

A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer – the 3JECROG P-01 study protocol
por: Li, Chen, et al.
Publicado: (2019)

Correction to: A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer – the 3JECROG P-01 study protocol
por: Li, Chen, et al.
Publicado: (2019)

Development and validation of a prediction model using molecular marker for long‐term survival in unresectable stage III non‐small cell lung cancer treated with chemoradiotherapy
por: Yang, Yufan, et al.
Publicado: (2021)

Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer
por: Lu, Xiaotong, et al.
Publicado: (2022)

Treatment outcomes of patients with stage III non–small cell lung cancer and interstitial lung diseases receiving intensity‐modulated radiation therapy: A single‐center experience of 85 cases
por: Wu, Linfang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oi00i5sivmg8iecv653fc598r6